INCY Share Price

Open 115.50 Change Price %
High 117.62 1 Day 2.44 2.12
Low 113.00 1 Week -0.22 -0.19
Close 117.53 1 Month 15.32 14.99
Volume 1155755 1 Year 43.28 58.29
52 Week High 121.18
52 Week Low 55.00
INCY Important Levels
Resistance 2 121.81
Resistance 1 120.05
Pivot 116.05
Support 1 115.01
Support 2 113.25
NASDAQ USA Most Active Stocks
FNFG 10.18 -0.20%
DRYS 1.01 -36.48%
DELL 13.86 0.22%
RFMD 16.59 -2.07%
RIMM 13.03 0.39%
BBEP 0.12 0.00%
GTAT 0.44 0.00%
SUSQ 14.20 -0.77%
ACAS 17.99 0.39%
MU 21.71 -2.73%
More..
NASDAQ USA Top Gainers Stocks
BGMD 0.07 133.33%
LOCM 0.09 50.00%
NFEC 1.28 40.66%
BASI 0.90 28.57%
URRE 2.68 27.62%
QKLS 0.14 27.27%
BSDM 0.62 26.53%
SNTA 0.34 25.93%
OTT 2.39 25.13%
GRVY 20.96 23.15%
More..
NASDAQ USA Top Losers Stocks
TXCC 0.01 -95.00%
HCIIP 10.10 -67.52%
CRMB 0.27 -57.81%
KIOR 0.03 -57.14%
AMCF 0.03 -50.00%
OSH 0.26 -49.02%
OSH 0.26 -49.02%
DVOX 0.05 -44.44%
PRXI 0.21 -43.24%
TRGT 0.96 -41.46%
More..

Incyte Corporation (NASDAQ: INCY)

INCY Technical Analysis 5
As on 19th Jan 2017 INCY Share Price closed @ 117.53 and we RECOMMEND Strong Buy for LONG-TERM with Stoploss of 85.69 & Strong Buy for SHORT-TERM with Stoploss of 103.46 we also expect STOCK to react on Following IMPORTANT LEVELS.
INCY Target for January
1st Target up-side N/A
2nd Target up-side N/A
3rd Target up-side N/A
1st Target down-side N/A
2nd Target down-side N/A
3rd Target down-side N/A
INCY Other Details
Segment EQ
Market Capital 2323686912.00
Sector Healthcare
Industry Biotechnology
Offical website http://www.incyte.com
INCY Address
INCY
Experimental Station
Route 141 & Henry Clay Road
Wilmington, DE 19880
United States
Phone: 302-498-6700
Interactive Technical Analysis Chart Incyte Corporation ( INCY NASDAQ USA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Incyte Corporation
INCY Business Profile
Incyte Corporation (Incyte) is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat serious unmet medical needs. Its advanced compound, JAKAFI (ruxolitinib), also known as INCB18424 and INC424, is an oral Janus associated kinase (JAK) inhibitor used for the treatment for patients with intermediate or high-risk myelofibrosis (MF), including primary MF, post-polycythemia vera MF and post-essential thrombocythemia MF. The Company has a second oral JAK1 and JAK2 inhibitor, LY3009104 (INCB28050), which is subject to a collaboration agreement with Eli Lilly and Company in which Lilly received worldwide development and commercialization rights for the compound for inflammatory and autoimmune diseases. In November 2011, JAKAFI became commercially available in the United States and is being marketed in the United States.